MK0249

· Merck Sharp & Dohme LLC

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for MK0249, covering 2010-11-18 to 2011-03-07. Get the full timeline:

Most recent: Clinical Trial Update: MK0249 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0249-016) [Phase 2]